Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1057347 | 0.99 | MAPK1 (0.42) | MAPK1OPRK1SMOMEN1ALDH1A1 | |
| SCHEMBL1063452 | 0.95 | SMO (0.43) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1063062 | 0.95 | SMO (0.42) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1062899 | 0.91 | SMN1; SMN2 (0.43) | MAPK1SMOMEN1ALDH1A1KMT2A | |
| SCHEMBL1060724 | 0.91 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10314238 | 0.88 | KMT2A (0.39) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4288547 | 0.88 | SMO (0.43) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1063689 | 0.87 | KMT2A (0.39) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1062880 | 0.87 | SMO (0.46) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1062882 | 0.87 | SMO (0.46) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247588-B1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | MAPK1 2681/4885OPRK1 362/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.